TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18-65 years old~* One or more mild-moderate TBI's characterized by loss of consciousness due to blast injury that is a minimum of one year old and occurred after 9/11/2001~* Absence of acute cardiac arrest or hemorrhagic shock at time of TBI.~* Absence of intracranial neurosurgery post-TBI~* Disability Rating Scale of 0-3~* Negative Michigan Alcohol Screening Test (MAST)~* Negative Drug Abuse Screening Test (DAST)~* Negative urine toxicology screen for drugs of abuse~* Negative pregnancy test in females~* Otherwise good health~* Less than 90% on the Percent Back to Normal Rating Scale~Exclusion Criteria:~* Pulmonary disease that precludes HBOT~* Unstable medical conditions that are contraindicated in HBOT~* Severe confinement anxiety~* Pregnancy~* Other pre-TBI neurological diagnoses~* Pre or post TBI history of substance abuse~* Pre or post TBI history of alcoholism.~* Participation in another experimental trial with active intervention.~* High probability of inability to complete the experimental protocol.~* Previous HBOT~* History of hospitalization for past TBI, stroke, nonfebrile seizures, or any seizure history other than seizure at the time of TBI~* Past or current history of mental retardation (baseline FSIQ \< 71.~* Pre/post-TBI history of systemic illness with impact on CNS (P.I.'s decision)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hyperbaric oxygen therapy-TBI/PCS (Type: EXPERIMENTAL): Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
- Hyperbaric Oxygen Therapy-PCS/PTSD (Type: EXPERIMENTAL): Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caudal Epidural Catheterization in Pediatric Renal Transplant: Effect on Hemodynamics and Pain After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3-12 years~* end stage renal disease~* no known allergy to bupivacaine~* both sexes~Exclusion Criteria:~* known allergy to bupivacaine~* inflammation at caudal area~* spinal cord deformity

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- caudal epidural catheterization group (Type: ACTIVE_COMPARATOR): 30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
- control group (Type: SHAM_COMPARATOR): 30 patients didn't receive caudal epidural analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants aged greater than or equal to (\>=) 2 and less than or equal to (\<=) 17 years~2. Clinical diagnosis of DS or LGS~3. Weight of \>=10 kilogram (kg) at the Screening visit~4. Currently taking 1 to 4 anti-epileptic drugs (AEDs) at a stable dose~5. Failed to become and remain seizure free with trials of at least 2 AEDs~Exclusion Criteria:~1. Has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit~2. Non-epileptic events that cannot be reliably distinguished from epileptic seizures~3. Participation in a clinical study involving another study drug in the previous month

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
- TAK-935 (Type: EXPERIMENTAL): TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing \<60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bispectral Index-guided Sedation for Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (\>18 years old) requiring elective flexible bronchoscopy or Real time endobronchial ultrasound with transbronchial needle aspiration.~Exclusion Criteria:~* American Society of Anesthesiologists classification of physical status 4 and 5, including hepatic or renal failure, severe obstructive sleep apnea and severe chronic obstructive pulmonary disease.~* Significant Central nervous system disorders or other factors contributing to access consciousness difficultly.~* Allergic history to study drugs.~* A history of glaucoma in the midazolam arm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIS-guided propofol infusion (Type: ACTIVE_COMPARATOR): In the study group, induction was started using alfentanil 4\~5μg/kg bolus following repeated propofol boluses (0.5\~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3\~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
- Clinical-judged midazolam administration (Type: ACTIVE_COMPARATOR): In the control group, induction was started using alfentanil 4\~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).~* Fasting glucose (FG) \< - 240 mg/dL, while on metformin or antidiabetic diet alone.~* HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%~Exclusion Criteria:~* Women of childbearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of asthma ≥ 1 year and diagnosed before 40 years old~* Uncontrolled asthma with double therapy only on medium doses of Inhaled CorticoSteroid (ICS) in combination with Long-acting beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5~* Pre-bronchodilator FEV1 \<80% of the predicted normal value~* Positive reversibility test~* At least 1 documented asthma exacerbation in the previous year~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening~* Current or ex-smokers (\>= 10 packs year)~* Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CHF 5993 100/6/12.5 µg (Type: EXPERIMENTAL): Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB
- CHF 1535 100/6 µg (Type: ACTIVE_COMPARATOR): Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment~* Easter Cooperative Oncology Group (ECOG) performance status 0 to 2~* Estimated life expectancy of at least 8 weeks~Exclusion Criteria:~* Known or suspected brain metastases~* Concurrent administration of any other tumor therapy~* Serious concomitant disorders~* Pregnancy or breast feeding~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pemetrexed plus carboplatin (Type: EXPERIMENTAL): Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum
- docetaxel plus carboplatin (Type: ACTIVE_COMPARATOR): Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, \>/=18 years of age~* epithelial ovarian, fallopian tube or primary peritoneal cancer~* platinum-resistant disease (disease progression within \<6 months of platinum therapy)~* EOCG performance status of 0-2~Exclusion Criteria:~* non-epithelial tumours~* ovarian tumours with low malignant potential~* previous treatment with \>2 chemotherapy regimens~* prior radiotherapy to the pelvis or abdomen

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 milligrams per square meter (mg/m\^2) as a 1-hour intravenous (IV) infusion on Days 1, 8, 15, and 22 every 4 weeks (q4w) OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 every 3 weeks \[q3w\]) OR pegylated liposomal doxorubicin (PLD) 40 mg/m\^2 as a 1 milligram per minute (mg/min) infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.
- Chemotherapy + Bevacizumab (Type: EXPERIMENTAL): Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion. Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 milligrams per kilogram (mg/kg) IV every 2 weeks (q2w; or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection of GEnetic Risk (EDGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Patients:~* Age 25 or older~* An active patient at a participating clinic (had at least one visit in the past 12 months)~* Comfortable reading and writing in English~Exclusion Criteria:~* Those who do not meet inclusion criteria.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Point of Care (Type: EXPERIMENTAL): For clinics in the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
- Direct Patient Engagement (Type: EXPERIMENTAL): For clinics in the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
- Stakeholder Interviews and Surveys (Type: NO_INTERVENTION): Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and follow-up. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific requirements~* Women of childbearing potential must have a negative pregnancy test, be non-lactating, and be using a highly effective form of birth control for 3 months prior to enrollment, during the study, and for 3 months after completion of all study-related proceed~* Male volunteers must be willing to use barrier contraception from the first day of dosing until 3 months after the last dose of IP.~* Have a body mass index (BMI) between 18 and 30 kg/m2, and weigh at least 50 kg~* Healthy male and/or female volunteers between the ages of 18 to 75 years inclusive, with veins on the back of both hands and both forearms suitable for cannulation or repeated venipuncture.~Exclusion Criteria:~* Use of any other investigational compound or participation in another clinical trial within 1 month prior to first administration of IP in this study~* History of any clinically significant disease or disorder (e.g., neurological, haematological, psychiatric, gastrointestinal, hepatic, renal disease)~* Positive serology result on screening for serum hepatitis B surface antigen, hepatitis C antibody (HCV), or human immunodeficiency virus (HIV)~* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs~* Any clinically significant abnormalities in the physical examination, lab, 12-lead ECG or vital signs as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): 600 mg ceftaroline fosamil in 50 ml infusion volume
- B (Type: PLACEBO_COMPARATOR): Placebo in 50 ml infusion volume
- C (Type: EXPERIMENTAL): 600 ceftaroline fosamil in 250 ml infusion volume
- D (Type: PLACEBO_COMPARATOR): Placebo in 250 ml infusion volume
- E (Type: EXPERIMENTAL): 600 mg ceftaroline in 100 ml infusion volume
- F (Type: PLACEBO_COMPARATOR): Placebo in 100 ml infusion volume

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is an out-patient 50 to 80 years old.~2. Has read, understood, signed and dated the informed consent.~3. Has indolent prostate cancer defined by:~   * Clinical Stage T1c or T2a.~  * Biopsy cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length \> 3 mm.~  * Absence of Grade 4 cells (Gleason \<7).~  * Prostate specific antigen (PSA) levels \<10 ng/ml.~4. Has a life expectancy \> 5 years.~5. Has accepted the principle of active surveillance.~6. Is willing to participate in the study for a minimum of fifteen months.~Exclusion Criteria:~1. Has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months.~2. Has psychological failure related to prostate cancer therapy.~3. Has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study.~4. Has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol.~5. Is under judicial protection, tutorship or curatorship.~6. Is unlikely to attend control visits.~7. Is currently enrolled in an investigational study or has participated in another investigational study within the last 3 months.~8. Has an allergy or hypersensitivity to any components of leuprorelin (Enantone LP) 11.25 mg or Casodex® 50 mg.~9. Has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause.~10. Has testosterone level \< 0.5 ng/ml.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Leuprorelin 11.25 mg (Type: EXPERIMENTAL): Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
- Active surveillance (Type: NO_INTERVENTION): Active surveillance is close medical monitoring of prostate cancer for any changes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete